LT3394084T - Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš krūties ir kitų tipų vėžį - Google Patents
Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš krūties ir kitų tipų vėžįInfo
- Publication number
- LT3394084T LT3394084T LTEP16802063.4T LT16802063T LT3394084T LT 3394084 T LT3394084 T LT 3394084T LT 16802063 T LT16802063 T LT 16802063T LT 3394084 T LT3394084 T LT 3394084T
- Authority
- LT
- Lithuania
- Prior art keywords
- peptides
- cancers
- combination
- breast cancer
- against breast
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 2
- 108090000765 processed proteins & peptides Proteins 0.000 title 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270968P | 2015-12-22 | 2015-12-22 | |
| GBGB1522667.3A GB201522667D0 (en) | 2015-12-22 | 2015-12-22 | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| PCT/EP2016/079059 WO2017108345A1 (en) | 2015-12-22 | 2016-11-29 | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3394084T true LT3394084T (lt) | 2021-05-25 |
Family
ID=55311455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16802063.4T LT3394084T (lt) | 2015-12-22 | 2016-11-29 | Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš krūties ir kitų tipų vėžį |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10213499B2 (lt) |
| EP (2) | EP3394084B1 (lt) |
| JP (2) | JP2019510465A (lt) |
| KR (1) | KR20180089522A (lt) |
| CN (1) | CN108602855A (lt) |
| AU (2) | AU2016375806B2 (lt) |
| BR (1) | BR112018009980A2 (lt) |
| CA (1) | CA3009286A1 (lt) |
| CO (1) | CO2018003860A2 (lt) |
| CR (4) | CR20200557A (lt) |
| DK (1) | DK3394084T3 (lt) |
| EA (1) | EA201891465A1 (lt) |
| ES (1) | ES2867880T3 (lt) |
| GB (1) | GB201522667D0 (lt) |
| HU (1) | HUE054453T2 (lt) |
| LT (1) | LT3394084T (lt) |
| MA (3) | MA44693B1 (lt) |
| MD (1) | MD3394084T2 (lt) |
| MX (1) | MX2018005273A (lt) |
| PE (1) | PE20181800A1 (lt) |
| PL (1) | PL3394084T3 (lt) |
| PT (1) | PT3394084T (lt) |
| RS (1) | RS61787B1 (lt) |
| SG (2) | SG10202005950XA (lt) |
| SI (1) | SI3394084T1 (lt) |
| TW (1) | TWI655205B (lt) |
| WO (1) | WO2017108345A1 (lt) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201609193D0 (en) | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| RS62544B1 (sr) | 2017-07-14 | 2021-12-31 | Immatics Biotechnologies Gmbh | Poboljšani polipeptidni molekul sa dvojnom specifičnošću |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| MX2020008327A (es) | 2018-02-09 | 2020-10-28 | Immatics Us Inc | Metodos para preparar celulas t. |
| WO2020059850A1 (ja) * | 2018-09-21 | 2020-03-26 | 国立大学法人東京大学 | がんの予後判定方法 |
| WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| EP3976805A1 (en) | 2019-05-27 | 2022-04-06 | Immatics US, Inc. | Viral vectors and their use in adoptive cellular therapy |
| CN114303060A (zh) | 2019-06-06 | 2022-04-08 | 伊玛提克斯生物技术有限公司 | 使用序列相似肽进行反向选择分选 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
| CN111979323A (zh) * | 2020-08-28 | 2020-11-24 | 深圳裕策生物科技有限公司 | 用于预测肿瘤免疫治疗效果的生物标志物检测方法及系统 |
| KR20230135589A (ko) | 2020-12-31 | 2023-09-25 | 이매틱스 유에스 인코포레이티드 | Cd8 폴리펩타이드, 조성물 및 이의 사용 방법 |
| JP2024503087A (ja) * | 2021-01-14 | 2024-01-24 | ロマ リンダ ユニヴァーシティ | 早期口腔扁平上皮癌の評価方法 |
| EP4334350A1 (en) | 2021-05-05 | 2024-03-13 | Immatics Biotechnologies GmbH | Bma031 antigen binding polypeptides |
| CN113528436B (zh) * | 2021-08-04 | 2023-01-17 | 苏州大学 | 基于淋巴细胞的同源靶向性人工抗原呈递细胞及其构建和应用 |
| WO2023025851A1 (en) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
| CN114685641B (zh) * | 2022-02-25 | 2024-03-08 | 西安交通大学医学院第一附属医院 | 一种抑制brca1/bard1复合体结合的多肽及其应用和防治癌症的药物 |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| WO2023212697A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| DK171727B1 (da) | 1978-12-22 | 1997-04-14 | Biogen Inc | Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| ES2108460T3 (es) | 1993-06-03 | 1997-12-16 | Therapeutic Antibodies Inc | Fragmentos de anticuerpos en terapeutica. |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US6805861B2 (en) | 1996-01-17 | 2004-10-19 | Imperial College Innovations Limited | Immunotherapy using cytotoxic T lymphocytes (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20030211510A1 (en) * | 1999-06-30 | 2003-11-13 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7211649B1 (en) * | 1999-07-02 | 2007-05-01 | Ana Mar Medical Ab | Cartilage intermediate layer protein |
| JP2004522404A (ja) | 1999-12-01 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 分泌及び膜貫通ポリペプチドとそれをコードしている核酸 |
| JP2003516344A (ja) * | 1999-12-13 | 2003-05-13 | エピミューン， インコーポレイテッド | Ｈｌａクラスｉａ２腫瘍関連抗原ペプチドおよびワクチン組成物 |
| WO2001046394A2 (en) * | 1999-12-21 | 2001-06-28 | Sugen, Inc. | Mammalian protein phosphatases |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| ATE472601T1 (de) | 2000-03-27 | 2010-07-15 | Technion Res And Dev Of Founda | Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung |
| ES2659376T3 (es) | 2000-06-05 | 2018-03-15 | Altor Bioscience Corporation | Proteínas de fusión del receptor de linfocitos T y conjugados y procedimientos de uso de las mismas |
| WO2002010369A1 (fr) | 2000-07-31 | 2002-02-07 | Kyogo Itoh | Antigene associe aux tumeurs |
| WO2002016939A2 (en) * | 2000-08-18 | 2002-02-28 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer and screening for cancer modulators |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| CA2476625A1 (en) | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| AU2003276403B2 (en) | 2002-11-09 | 2010-04-15 | Adaptimmune Limited | T cell receptor display |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| WO2005007090A2 (en) * | 2003-07-03 | 2005-01-27 | President And Fellows Of Harvard College | Inhibitors of the map kinase pathway |
| WO2006010051A2 (en) | 2004-07-07 | 2006-01-26 | Metabolex, Inc. | Methods of diagnosing & treating diabetes and insulin resistance |
| PT1806359E (pt) | 2005-09-05 | 2010-05-25 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii |
| JP2011502964A (ja) * | 2007-10-23 | 2011-01-27 | ザ レジェンツ オブ ザ ユニバーシティ オブ コロラド | インバリアント鎖発現および／または異所性ｃｌｉｐ結合の競合的阻害剤 |
| KR100999043B1 (ko) * | 2007-12-04 | 2010-12-09 | 한국생명공학연구원 | 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법 |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| EP2119726B2 (en) * | 2008-05-14 | 2017-11-29 | Immatics Biotechnologies GmbH | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| CA2816225A1 (en) | 2010-10-26 | 2012-05-03 | Technion Research & Development Foundation Ltd. | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| WO2014010231A1 (en) * | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Kif20a epitope peptides for th1 cells and vaccines containing the same |
| CA2879024A1 (en) * | 2012-07-12 | 2014-01-16 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| GB201214007D0 (en) * | 2012-08-07 | 2012-09-19 | Scancell Ltd | Anti-tumour immune responses to modified self-epitopes |
| WO2014071978A1 (en) | 2012-11-08 | 2014-05-15 | Roche Diagnostics Gmbh | Nucleic acids encoding chimeric polypeptides for library screening |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI714869B (zh) * | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物 |
| GB201319446D0 (en) * | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
-
2015
- 2015-12-22 GB GBGB1522667.3A patent/GB201522667D0/en not_active Ceased
-
2016
- 2016-11-29 PE PE2018000415A patent/PE20181800A1/es unknown
- 2016-11-29 WO PCT/EP2016/079059 patent/WO2017108345A1/en active Application Filing
- 2016-11-29 DK DK16802063.4T patent/DK3394084T3/da active
- 2016-11-29 PL PL16802063T patent/PL3394084T3/pl unknown
- 2016-11-29 SG SG10202005950XA patent/SG10202005950XA/en unknown
- 2016-11-29 AU AU2016375806A patent/AU2016375806B2/en not_active Ceased
- 2016-11-29 CR CR20200557A patent/CR20200557A/es unknown
- 2016-11-29 MA MA44693A patent/MA44693B1/fr unknown
- 2016-11-29 CN CN201680075076.8A patent/CN108602855A/zh active Pending
- 2016-11-29 MX MX2018005273A patent/MX2018005273A/es unknown
- 2016-11-29 MD MDE20181036T patent/MD3394084T2/ro unknown
- 2016-11-29 US US16/065,681 patent/US10213499B2/en active Active
- 2016-11-29 PT PT168020634T patent/PT3394084T/pt unknown
- 2016-11-29 CA CA3009286A patent/CA3009286A1/en active Pending
- 2016-11-29 KR KR1020187020794A patent/KR20180089522A/ko not_active Application Discontinuation
- 2016-11-29 CR CR20180135A patent/CR20180135A/es unknown
- 2016-11-29 JP JP2018521114A patent/JP2019510465A/ja active Pending
- 2016-11-29 ES ES16802063T patent/ES2867880T3/es active Active
- 2016-11-29 SI SI201631179T patent/SI3394084T1/sl unknown
- 2016-11-29 MA MA44101A patent/MA44101B1/fr unknown
- 2016-11-29 CR CR20200556A patent/CR20200556A/es unknown
- 2016-11-29 RS RS20210548A patent/RS61787B1/sr unknown
- 2016-11-29 MA MA42020A patent/MA42020A1/fr unknown
- 2016-11-29 HU HUE16802063A patent/HUE054453T2/hu unknown
- 2016-11-29 LT LTEP16802063.4T patent/LT3394084T/lt unknown
- 2016-11-29 EP EP16802063.4A patent/EP3394084B1/en active Active
- 2016-11-29 EA EA201891465A patent/EA201891465A1/ru unknown
- 2016-11-29 BR BR112018009980-5A patent/BR112018009980A2/pt active Search and Examination
- 2016-11-29 EP EP21162594.2A patent/EP3875467A3/en active Pending
- 2016-11-29 SG SG11201801384YA patent/SG11201801384YA/en unknown
- 2016-11-29 CR CR20200555A patent/CR20200555A/es unknown
- 2016-12-20 US US15/384,963 patent/US10064929B2/en active Active
- 2016-12-22 TW TW105142661A patent/TWI655205B/zh active
-
2018
- 2018-04-11 CO CONC2018/0003860A patent/CO2018003860A2/es unknown
-
2020
- 2020-12-16 AU AU2020289763A patent/AU2020289763B2/en active Active
-
2021
- 2021-04-29 JP JP2021076900A patent/JP2021121194A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210709T8 (hr) | Peptidi i kombinacija peptida za imunoterapiju protiv karcinoma prostate i druge vrste karcinoma | |
| ZA201801036B (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| SG10202005950XA (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| GB201511792D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers | |
| HK1252868A1 (zh) | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 | |
| SG10202001665QA (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
| SG11201706155XA (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | |
| HK1255542A1 (zh) | 用於食管癌和其他癌症免疫治療的新型肽和肽組合物 | |
| IL280879A (en) | Innovative peptides and a combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |